• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估治疗模式改变对 MS 长期预后改善的影响。

Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.

机构信息

Multiple Sclerosis Center, Spedali Civili di Brescia, Montichiari Hospital, Montichiari, Italy/University of Genoa, Genoa, Italy.

Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

出版信息

Mult Scler. 2017 Nov;23(13):1757-1761. doi: 10.1177/1352458516687402. Epub 2017 Jan 12.

DOI:10.1177/1352458516687402
PMID:28080255
Abstract

OBJECTIVE

To assess whether the age at which multiple sclerosis (MS) patients reach Expanded Disability Status Scale (EDSS) milestones changed as long as new drugs for the treatment of MS became available.

METHODS

We evaluated the long-term impact of therapies on disability progression assessing whether there is a detectable delay in the age at which patients reached EDSS milestones in more recent years. We used data collected over more than 30 years in the Center of Brescia, Italy. We compared the age at EDSS = 6 among patients diagnosed with relapsing-remitting MS in different time periods, adjusting for age at diagnosis and median interval among EDSS visits, by a multivariate Cox model.

RESULTS

A total of 1324 MS patients were included. Patients diagnosed in more recent periods reached EDSS = 6 at an older age: the rate at which patients reached EDSS = 6 in those diagnosed in 1991-1995 was similar to those diagnosed in 1980-1990 (hazard ratio ( HR) = 1.09, p = 0.68) and to those diagnosed in 1996-2000 ( HR = 0.85, p = 0.44), it was reduced by 37% in patients diagnosed in 2001-2005 ( HR = 0.63, p = 0.05), by 46% in patients diagnosed in 2006-2010 ( HR = 0.54, p < 0.02).

CONCLUSION

A clear modification of MS course is observed after 2000; among other causes, this can be associated to the changes in the treatment patterns experienced in those years.

摘要

目的

评估多发性硬化症(MS)患者达到扩展残疾状况量表(EDSS)里程碑的年龄是否随着新的 MS 治疗药物的出现而改变。

方法

我们评估了治疗对残疾进展的长期影响,以确定在最近几年,患者达到 EDSS 里程碑的年龄是否存在可检测的延迟。我们使用了意大利布雷西亚中心超过 30 年收集的数据。我们通过多变量 Cox 模型比较了不同时间段被诊断为复发缓解型 MS 的患者在 EDSS = 6 时的年龄,调整了诊断时的年龄和 EDSS 就诊的中位数间隔。

结果

共纳入 1324 名 MS 患者。在最近时间段被诊断的患者达到 EDSS = 6 的年龄更大:1991-1995 年被诊断的患者达到 EDSS = 6 的速度与 1980-1990 年被诊断的患者相似(风险比(HR)= 1.09,p = 0.68)和 1996-2000 年被诊断的患者(HR = 0.85,p = 0.44),2001-2005 年被诊断的患者减少了 37%(HR = 0.63,p = 0.05),2006-2010 年被诊断的患者减少了 46%(HR = 0.54,p < 0.02)。

结论

2000 年后观察到 MS 病程的明显改变;其中一个原因可能与这些年治疗模式的变化有关。

相似文献

1
Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.评估治疗模式改变对 MS 长期预后改善的影响。
Mult Scler. 2017 Nov;23(13):1757-1761. doi: 10.1177/1352458516687402. Epub 2017 Jan 12.
2
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.近几十年来多发性硬化症达到残疾里程碑风险的变化:瑞典一项全国范围内基于人群的队列研究。
JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330.
3
Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.长期口服避孕药的使用对复发性缓解型多发性硬化临床病程的影响。
Fertil Steril. 2014 Jul;102(1):116-22. doi: 10.1016/j.fertnstert.2014.03.054. Epub 2014 Apr 29.
4
Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.疲劳预示着复发缓解型多发性硬化症患者的病情恶化。
Mult Scler. 2016 Dec;22(14):1841-1849. doi: 10.1177/1352458516635874. Epub 2016 Feb 26.
5
Natural history of secondary-progressive multiple sclerosis.继发进展型多发性硬化的自然史。
Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21.
6
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.干扰素β治疗与复发缓解型多发性硬化患者残疾进展的相关性。
JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.
7
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症的复发及随后残疾状况的恶化
Neurology. 2006 Sep 12;67(5):804-8. doi: 10.1212/01.wnl.0000234064.17156.03.
8
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?疾病修正药物在延缓复发型多发性硬化症进展方面的效果如何?
Neurology. 2007 Oct 9;69(15):1498-507. doi: 10.1212/01.wnl.0000271884.11129.f3. Epub 2007 Aug 15.
9
Self-reported levels of education and disability progression in multiple sclerosis.多发性硬化症患者自我报告的教育水平与残疾进展情况
Acta Neurol Scand. 2016 Dec;134(6):414-419. doi: 10.1111/ane.12555. Epub 2016 Jan 6.
10
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.新诊断的复发型多发性硬化症患者长期停用干扰素的预测因素。
Mult Scler Relat Disord. 2016 Nov;10:90-96. doi: 10.1016/j.msard.2016.09.011. Epub 2016 Sep 28.

引用本文的文献

1
System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment.阿尔茨海默病诊断与治疗的系统准备情况及患者护理路径
Alzheimers Dement (N Y). 2025 Jun 19;11(2):e70094. doi: 10.1002/trc2.70094. eCollection 2025 Apr-Jun.
2
Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.复发相关和复发无关因素对不同时期诊断的多发性硬化症患者总体扩展残疾状态量表进展的影响
Ann Neurol. 2024 Oct 9;97(1):95-103. doi: 10.1002/ana.27093.
3
Pediatric Onset Multiple Sclerosis and Obesity: Defining the Silhouette of Disease Features in Overweight Patients.
儿科发病多发性硬化症与肥胖:超重患者疾病特征轮廓的定义。
Nutrients. 2023 Nov 22;15(23):4880. doi: 10.3390/nu15234880.
4
Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.从多发性硬化症患者的行政索赔数据中看现实世界的疾病修正治疗途径。
BMC Neurol. 2022 Jun 7;22(1):211. doi: 10.1186/s12883-022-02738-7.
5
Motor evoked potentials for multiple sclerosis, a multiyear follow-up dataset.多发性硬化症的运动诱发电位,多年随访数据集。
Sci Data. 2022 May 16;9(1):207. doi: 10.1038/s41597-022-01335-0.
6
Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study.以色列阿什肯纳兹犹太人与非阿什肯纳兹犹太患者多发性硬化症临床和流行病学特征的差异:一项回顾性单中心研究。
Sci Rep. 2022 Mar 16;12(1):4555. doi: 10.1038/s41598-022-08565-7.
7
Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.西尼莫德治疗意大利多发性硬化症继发进展期的成本效果和预算影响分析。
PLoS One. 2022 Mar 8;17(3):e0264123. doi: 10.1371/journal.pone.0264123. eCollection 2022.
8
The need for a strategic therapeutic approach: multiple sclerosis in check.采取战略性治疗方法的必要性:控制多发性硬化症。
Ther Adv Chronic Dis. 2022 Jan 18;13:20406223211063032. doi: 10.1177/20406223211063032. eCollection 2022.
9
Apparent changes in the epidemiology and severity of multiple sclerosis.多发性硬化症的流行病学和严重程度的明显变化。
Nat Rev Neurol. 2021 Nov;17(11):676-688. doi: 10.1038/s41582-021-00556-y. Epub 2021 Sep 28.
10
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.在接受克拉屈滨片 3.5mg/kg 治疗的复发性多发性硬化症患者中,通过扩展残疾状况量表评估的长期疾病稳定性:CLARITY 和 CLARITY 扩展研究的探索性事后分析。
Adv Ther. 2021 Sep;38(9):4975-4985. doi: 10.1007/s12325-021-01865-w. Epub 2021 Aug 9.